Endolytix

Overview

Endolytix is developing a therapy to treat non-tuberculous mycobacterial pulmonary disease (NTM-PD). NTM-PD is a difficult to treat chronic respiratory disease characterized by high rates of recurrence. There is a need for new therapies to disrupt the standard of care as the current treatment regimen has poor efficacy and tolerability that limits the number of eligible patients, while also having 12+ month treatment timelines. During infection, NTMs target and infect macrophages in the lung, allowing them to hide from the immune system and antibiotics. Endolytix’s approach utilizes a cocktail of phage lysins delivered in proprietary inhaled liposome formulations that can target macrophages and the pathogens hiding within them.